Over $1 million spent advertising Trulicity in medical journals in January 2015

It's a new year, which can often mean new pharmaceuticals making big investments advertising in print medical journals. For example, Trulicity—approved in September 2014 for Type 2 Diabetes treatment—has hit the ground running with more than a million dollar print journal ad expenditure. For that investment, Trulicity has garnered 2.5% of the total share among all pharmaceuticals.

Top 5 Print Ad Drugs (Dollars): January 2015
  1. Trulicity – $1 MM (N/A)
  2. Invokana – $799,000 (-59%)
  3. Gazyva Obinutuzumab Injection – $724,000 (+163%)
  4. Xarelto Tablets – $569,000 (-59%)
  5. Eliquis Tablets – $525,000 (+88%)

The percentage changes compare January 2015 to January 2014. For more information on these ad insights or other data, let us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.

Search article